xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05984901</url>
    </required_header>
    <id_info>
      <org_study_id>IRAS: 317899</org_study_id>
      <nct_id>NCT05984901</nct_id>
    </id_info>
    <brief_title>The CAVA Multicentre Dizziness Trial</brief_title>
    <acronym>CAVA 2</acronym>
    <official_title>Continuous Ambulatory Vestibular Assessment (CAVA): Development of a System to Provide an Automatic Diagnosis for Vestibular Conditions</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>University Hospitals, Leicester</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>St George's University Hospitals NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Gloucestershire Hospitals NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>University Hospital Birmingham NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Mid and South Essex NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Norfolk and Norwich University Hospitals NHS Foundation Trust</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the&#xD;
        extent to which the CAVA system can differentiate three common inner-ear causes of dizziness:&#xD;
        Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).&#xD;
  &#xD;
        The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that&#xD;
        adhere to the left and right side of the participant's face; and a small reusable module&#xD;
        fitting over the ear that contains a battery, microcomputer data storage facility and&#xD;
        connection ports for the arrays. The CAVA device will be worn by all participants for 30 days&#xD;
        with the aim of capturing eye movement data during a dizzy attack.&#xD;
  &#xD;
        The first objective is to develop an algorithm that can discriminate between the 3 listed&#xD;
        dizziness conditions. The second is to quantify the financial and patient benefits of&#xD;
        deployment in the NHS. The final objective is to expedite a plan to deploy the system in the&#xD;
        NHS.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a multicentre diagnostic accuracy study with a recruitment target of 255 adult&#xD;
        participants. Recruitment will take place across ten sites in the UK, over two years. To be&#xD;
        eligible, participants must have an existing diagnosis of Ménière's disease, vestibular&#xD;
        migraine or BPPV. The study will recruit eighty-five participants with each condition. Each&#xD;
        patient's diagnosis will form the &quot;reference standard&quot; which will later be compared with a&#xD;
        automated computer diagnosis.&#xD;
  &#xD;
        Each participant will wear the CAVA device near continuously for thirty days. The device will&#xD;
        record all eye and head movements during this time, including during any episodes of vertigo.&#xD;
        When a patient experiences an episode of vertigo, they will be asked to activate an event&#xD;
        marker on the CAVA device and keep a written record of attack onset and duration in a diary.&#xD;
        Although this manual logging will not be relied upon for algorithm development, the whole 30&#xD;
        days of data will be used to detect periods of eye movement associated with dizziness.&#xD;
  &#xD;
        The investigators will develop computer algorithms that use the data captured by the CAVA&#xD;
        devices to differentiate between three target conditions. These algorithms will build on the&#xD;
        algorithms that have been developed during the current MRC grant which have produced&#xD;
        excellent results.10,11,17. The algorithms use deep learning neural networks (DNNs) in a&#xD;
        so-called 'end-to-end' approach. In this approach, a multi-layered network takes as input&#xD;
        'raw' time domain data and outputs a classification decision without using any explicit&#xD;
        intermediate representations of the signal (such as signal entropy, power, skewness, kurtosis&#xD;
        etc.). End-to-end approaches, which typically utilise alternating sequences of convolution&#xD;
        and pooling layers, fully connected layers, auto-encoders and long short-term memory (LSTM)&#xD;
        layers, have been shown to outperform traditional approaches in cases where large amounts of&#xD;
        training data are available. However, they provide little insight into how they work (i.e.,&#xD;
        which features of the signal are important for classification). It will therefore also be&#xD;
        considered to develop methods in which intermediate representations are generated and then&#xD;
        use these input features to test a range of classifiers (e.g., boosted trees, random forests,&#xD;
        logistic regression, support vector machines etc.).&#xD;
  &#xD;
        The performance of the algorithms will be assessed using the 'leave-one-out cross-validation'&#xD;
        technique, which is the usual way of evaluating classifiers.22 In this technique, the data&#xD;
        from a single patient is set aside and the remaining data from the other patients is used to&#xD;
        'train' the classifier. A algorithm will be referred to that is trained to distinguish the&#xD;
        three conditions as a 'classifier'. The classifier is then tested on the set aside data: the&#xD;
        testing process consists of comparing the classifier's predicted diagnosis ('Ménière's&#xD;
        disease', 'vestibular migraine' or 'BPPV') with the true diagnosis (the reference standard&#xD;
        label). This process is repeated, removing a different patient's data each time, producing an&#xD;
        automated diagnosis for all 255 patients. Although computationally expensive, this ensures&#xD;
        that the classifier has not 'seen' during training the data from the patient it tests, which&#xD;
        would bias its decision. It also closely matches the real-world scenario of a new patient&#xD;
        presenting to their clinician and a diagnosis being provided on the basis of their experience&#xD;
        of other patients.&#xD;
  &#xD;
        The study will present the sensitivity and specificity for diagnosing each of the three&#xD;
        target conditions and Receiver Operator Curves (ROCs), showing how the diagnostic accuracy&#xD;
        changes for various classification thresholds.&#xD;
  &#xD;
        The target conditions have different incidences. Reflecting this imbalance in this study's&#xD;
        statistical calculations would require many thousands of patients with the most common of&#xD;
        these conditions. It is believed that this would not be economically viable and would not add&#xD;
        value to the study. The results obtained will be sufficiently robust to demonstrate the&#xD;
        system's efficacy and the expected detection rate for each disease.&#xD;
  &#xD;
        A Health Economist (HE) will assess the potential resource, financial savings and patient&#xD;
        benefits of a diagnostic pathway incorporating CAVA compared to existing pathways. The study&#xD;
        design ensures that appropriate data collection is embedded into the study for the economic&#xD;
        evaluation. An early cost-effectiveness model will be developed using retrospective patient&#xD;
        data (e.g., history, number of tests and hospital visits). The model will reveal the&#xD;
        potential savings and benefits of CAVA's predictive algorithms at various hypothetical&#xD;
        thresholds of diagnostic accuracy versus a standard diagnostic pathway. A counterfactual&#xD;
        pathway of diagnosis with the CAVA device will be developed against standard of usual care at&#xD;
        the moment, to inform the most likely potential economic benefits.&#xD;
  &#xD;
        A commercialisation consultant will oversee a portfolio of work to support the&#xD;
        commercialisation of the CAVA system. They will produce a market access plan detailing CAVA's&#xD;
        route to commercialisation and confirm CAVA's placement within existing NHS pathways and how&#xD;
        it would be implemented. The Investigators will build upon the previous focus-group work with&#xD;
        a stakeholders' event involving professionals, patients, and IT stakeholders from NHS&#xD;
        organisations. The investigators will identify the issues important to stakeholders regarding&#xD;
        the feasibility of adoption within the NHS and will establish support for adoption. A PPI&#xD;
        event will be hosted to review the interim findings from the trial and a public dissemination&#xD;
        event to share the findings with the public. Throughout the project prospective licenses will&#xD;
        be engaged.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">April 1, 2022</start_date>
    <completion_date type="Anticipated">March 31, 2025</completion_date>
    <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>All participants fulfilling the eligibility criteria and providing consent will wear the CAVA device for 30 days. The CAVA algorithm will then diagnose each patient based only on the data recorded from the device. The accuracy of the system will be tested by comparing the CAVA system's diagnosis with each patient's known diagnosis. The results of the algorithm work (&quot;the diagnosis&quot;) will not be available until the end of the trial and will not be made available to clinicians or patients during the trial.</intervention_model_description>
      <primary_purpose>Diagnostic</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Success of a diagnostic device to diagnose different inner-ear conditions</measure>
      <time_frame>30 Days</time_frame>
      <description>The primary outcome is the success of a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.&#xD;
  The investigators will develop computer algorithms that use the data captured by the CAVA devices to differentiate between the three target conditions. The algorithms use deep learning neural networks (DNNs) in a so-called 'end-to-end' approach. In this approach, a multi-layered network takes as input 'raw' time domain data and outputs a classification decision without using any explicit intermediate representations of the signal (such as signal entropy, power, skewness, kurtosis etc.)</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Health economics data</measure>
      <time_frame>30 Days</time_frame>
      <description>Health economics data will inform analysis of potential financial and patient benefits of a diagnostic pathway incorporating the CAVA system compared to existing pathways. An early cost-effectiveness model will be developed using retrospective patient data.&#xD;
  The data will be used to estimate the frequency of likely NHS resource-use of patients under observation with one of the three diagnoses, to determine the likely cost and Health-related quality of life impacts of each. It will also be used to assess the prevalence of time-off-work (productivity), reduced productivity and reduce non-paid activities e.g., volunteering, caring etc. as well as insights into early- retirements or changes in occupation etc.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">255</enrollment>
    <condition>Ménière's Disease</condition>
    <condition>Vestibular Migraine</condition>
    <condition>Benign Paroxysmal Positional Vertigo (BPPV)</condition>
    <arm_group>
      <arm_group_label>The CAVA Multicentre Dizziness Trial (CAVA2)</arm_group_label>
      <arm_group_type>Other</arm_group_type>
      <description>CAVA 2 is a single arm study testing a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>The continuous ambulatory vestibular assessment (CAVA) system</intervention_name>
      <description>The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).&#xD;
  The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.&#xD;
  The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS.</description>
      <arm_group_label>The CAVA Multicentre Dizziness Trial (CAVA2)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Age 18 and over&#xD;
  &#xD;
            2. Must have relevant index medical condition: Ménière's Disease, Vestibular Migraine,&#xD;
               posterior canal Benign Paroxysmal Positional Vertigo (see section 6.3.1.2 for specific&#xD;
               criteria)&#xD;
  &#xD;
            3. Experiencing episodes of true vertigo with at least 2 episodes within the preceding 4&#xD;
               weeks at time of consent&#xD;
  &#xD;
            4. The duration and nature of the vertigo is of a duration and a nature supportive of the&#xD;
               relevant index medical condition&#xD;
  &#xD;
            5. Owns and able to use a telephone&#xD;
  &#xD;
            6. Willing to provide informed consent&#xD;
  &#xD;
            7. Willing to comply with the study protocol for using the CAVA device&#xD;
  &#xD;
            8. Willing to complete all study materials&#xD;
  &#xD;
            9. Adequate grasp of the English language or language used within an existing translated&#xD;
               version of the informed consent form and patient information sheet and where hospital&#xD;
               translators are available to provide support&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Has an allergy to plasters and/or medical adhesives&#xD;
  &#xD;
            2. Evidence of dermatitis, fragile skin, or any other condition that could be aggravated&#xD;
               by the repeated application of skin surface adhesives&#xD;
  &#xD;
            3. Pregnant or breastfeeding mothers&#xD;
  &#xD;
            4. Bilateral or second side Ménière's Disease&#xD;
  &#xD;
            5. Active bilateral or second side posterior canal Benign Paroxysmal Positional Vertigo&#xD;
  &#xD;
            6. Currently enrolled on an intervention trial (not including questionnaire-based or&#xD;
               observational trial)&#xD;
  &#xD;
            7. Patients who meet diagnostic criteria for more than one eligible condition at time of&#xD;
               recruitment&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>John Phillips, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Consultant ENT Surgeon</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>John Phillips, PhD</last_name>
      <phone>(+44)01379 788320</phone>
      <phone_ext>x5283</phone_ext>
      <email>john.phillips@nnuh.nhs.uk</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Juliet High</last_name>
      <phone>+44 (0)1603 59 1708</phone>
      <email>j.high@uea.ac.uk</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Norfolk and Norwich University Hospitals Foundation Trust</name>
        <address>
          <city>Norwich</city>
          <state>Norfolk</state>
          <zip>NR4 7UY</zip>
          <country>United Kingdom</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>John Phillips, PhD</last_name>
        <email>john.phillips@nnuh.nhs.uk</email>
      </contact>
      <investigator>
        <last_name>John Phillips, PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United Kingdom</country>
    </location_countries>
    <verification_date>March 2023</verification_date>
    <study_first_submitted>May 2, 2023</study_first_submitted>
    <study_first_submitted_qc>August 2, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 2, 2023</last_update_submitted>
    <last_update_submitted_qc>August 2, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Vertigo</mesh_term>
      <mesh_term>Meniere Disease</mesh_term>
      <mesh_term>Benign Paroxysmal Positional Vertigo</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05984901
  org study id: IRAS: 317899
  nct id: NCT05984901
  lead sponsor: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the
        extent to which the CAVA system can differentiate three common inner-ear causes of dizziness:
        Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).
  
        The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that
        adhere to the left and right side of the participant's face; and a small reusable module
        fitting over the ear that contains a battery, microcomputer data storage facility and
        connection ports for the arrays. The CAVA device will be worn by all participants for 30 days
        with the aim of capturing eye movement data during a dizzy attack.
  
        The first objective is to develop an algorithm that can discriminate between the 3 listed
        dizziness conditions. The second is to quantify the financial and patient benefits of
        deployment in the NHS. The final objective is to expedite a plan to deploy the system in the
        NHS.
  This is a multicentre diagnostic accuracy study with a recruitment target of 255 adult
        participants. Recruitment will take place across ten sites in the UK, over two years. To be
        eligible, participants must have an existing diagnosis of Ménière's disease, vestibular
        migraine or BPPV. The study will recruit eighty-five participants with each condition. Each
        patient's diagnosis will form the "reference standard" which will later be compared with a
        automated computer diagnosis.
  
        Each participant will wear the CAVA device near continuously for thirty days. The device will
        record all eye and head movements during this time, including during any episodes of vertigo.
        When a patient experiences an episode of vertigo, they will be asked to activate an event
        marker on the CAVA device and keep a written record of attack onset and duration in a diary.
        Although this manual logging will not be relied upon for algorithm development, the whole 30
        days of data will be used to detect periods of eye movement associated with dizziness.
  
        The investigators will develop computer algorithms that use the data captured by the CAVA
        devices to differentiate between three target conditions. These algorithms will build on the
        algorithms that have been developed during the current MRC grant which have produced
        excellent results.10,11,17. The algorithms use deep learning neural networks (DNNs) in a
        so-called 'end-to-end' approach. In this approach, a multi-layered network takes as input
        'raw' time domain data and outputs a classification decision without using any explicit
        intermediate representations of the signal (such as signal entropy, power, skewness, kurtosis
        etc.). End-to-end approaches, which typically utilise alternating sequences of convolution
        and pooling layers, fully connected layers, auto-encoders and long short-term memory (LSTM)
        layers, have been shown to outperform traditional approaches in cases where large amounts of
        training data are available. However, they provide little insight into how they work (i.e.,
        which features of the signal are important for classification). It will therefore also be
        considered to develop methods in which intermediate representations are generated and then
        use these input features to test a range of classifiers (e.g., boosted trees, random forests,
        logistic regression, support vector machines etc.).
  
        The performance of the algorithms will be assessed using the 'leave-one-out cross-validation'
        technique, which is the usual way of evaluating classifiers.22 In this technique, the data
        from a single patient is set aside and the remaining data from the other patients is used to
        'train' the classifier. A algorithm will be referred to that is trained to distinguish the
        three conditions as a 'classifier'. The classifier is then tested on the set aside data: the
        testing process consists of comparing the classifier's predicted diagnosis ('Ménière's
        disease', 'vestibular migraine' or 'BPPV') with the true diagnosis (the reference standard
        label). This process is repeated, removing a different patient's data each time, producing an
        automated diagnosis for all 255 patients. Although computationally expensive, this ensures
        that the classifier has not 'seen' during training the data from the patient it tests, which
        would bias its decision. It also closely matches the real-world scenario of a new patient
        presenting to their clinician and a diagnosis being provided on the basis of their experience
        of other patients.
  
        The study will present the sensitivity and specificity for diagnosing each of the three
        target conditions and Receiver Operator Curves (ROCs), showing how the diagnostic accuracy
        changes for various classification thresholds.
  
        The target conditions have different incidences. Reflecting this imbalance in this study's
        statistical calculations would require many thousands of patients with the most common of
        these conditions. It is believed that this would not be economically viable and would not add
        value to the study. The results obtained will be sufficiently robust to demonstrate the
        system's efficacy and the expected detection rate for each disease.
  
        A Health Economist (HE) will assess the potential resource, financial savings and patient
        benefits of a diagnostic pathway incorporating CAVA compared to existing pathways. The study
        design ensures that appropriate data collection is embedded into the study for the economic
        evaluation. An early cost-effectiveness model will be developed using retrospective patient
        data (e.g., history, number of tests and hospital visits). The model will reveal the
        potential savings and benefits of CAVA's predictive algorithms at various hypothetical
        thresholds of diagnostic accuracy versus a standard diagnostic pathway. A counterfactual
        pathway of diagnosis with the CAVA device will be developed against standard of usual care at
        the moment, to inform the most likely potential economic benefits.
  
        A commercialisation consultant will oversee a portfolio of work to support the
        commercialisation of the CAVA system. They will produce a market access plan detailing CAVA's
        route to commercialisation and confirm CAVA's placement within existing NHS pathways and how
        it would be implemented. The Investigators will build upon the previous focus-group work with
        a stakeholders' event involving professionals, patients, and IT stakeholders from NHS
        organisations. The investigators will identify the issues important to stakeholders regarding
        the feasibility of adoption within the NHS and will establish support for adoption. A PPI
        event will be hosted to review the interim findings from the trial and a public dissemination
        event to share the findings with the public. Throughout the project prospective licenses will
        be engaged.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: All participants fulfilling the eligibility criteria and providing consent will wear the CAVA device for 30 days. The CAVA algorithm will then diagnose each patient based only on the data recorded from the device. The accuracy of the system will be tested by comparing the CAVA system's diagnosis with each patient's known diagnosis. The results of the algorithm work ("the diagnosis") will not be available until the end of the trial and will not be made available to clinicians or patients during the trial.
  primary purpose: Diagnostic
  masking: None (Open Label)
  measure: Success of a diagnostic device to diagnose different inner-ear conditions
  time frame: 30 Days
  description: The primary outcome is the success of a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.
  The investigators will develop computer algorithms that use the data captured by the CAVA devices to differentiate between the three target conditions. The algorithms use deep learning neural networks (DNNs) in a so-called 'end-to-end' approach. In this approach, a multi-layered network takes as input 'raw' time domain data and outputs a classification decision without using any explicit intermediate representations of the signal (such as signal entropy, power, skewness, kurtosis etc.)
  measure: Health economics data
  time frame: 30 Days
  description: Health economics data will inform analysis of potential financial and patient benefits of a diagnostic pathway incorporating the CAVA system compared to existing pathways. An early cost-effectiveness model will be developed using retrospective patient data.
  The data will be used to estimate the frequency of likely NHS resource-use of patients under observation with one of the three diagnoses, to determine the likely cost and Health-related quality of life impacts of each. It will also be used to assess the prevalence of time-off-work (productivity), reduced productivity and reduce non-paid activities e.g., volunteering, caring etc. as well as insights into early- retirements or changes in occupation etc.
  arm group label: The CAVA Multicentre Dizziness Trial (CAVA2)
  arm group type: Other
  description: CAVA 2 is a single arm study testing a diagnostic device to diagnose different inner-ear conditions appraised by calculating values for sensitivity and specificity. Head and eye movements recorded by the CAVA device will enable the computer algorithms (to be developed) to differentiate between the three target conditions.
  intervention type: Device
  intervention name: The continuous ambulatory vestibular assessment (CAVA) system
  description: The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).
  The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.
  The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS.
  arm group label: The CAVA Multicentre Dizziness Trial (CAVA2)
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: John Phillips, PhD
  role: Principal Investigator
  affiliation: Consultant ENT Surgeon
  last name: John Phillips, PhD
  phone: (+44)01379 788320
  phone ext: x5283
  email: john.phillips@nnuh.nhs.uk
  last name: Juliet High
  phone: +44 (0)1603 59 1708
  email: j.high@uea.ac.uk
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  country: United Kingdom
  responsible party type: Sponsor
  mesh term: Vertigo
  mesh term: Meniere Disease
  mesh term: Benign Paroxysmal Positional Vertigo